Single-arm two-stage designs for phase II of clinical trials typically focus on a binary endpoint obtained by dichotomising an underlying continuous measure of treatment efficacy. To avoid the resulting loss of information, we propose a two-stage design based on a Bayesian predictive approach that directly uses the original continuous endpoint. Numerical results are provided with reference to phase II cancer trials aimed at assessing tumour shrinking effect of an experimental treatment.
Continuous endpoints in Bayesian two-stage designs / Brutti, Pierpaolo; Fulvio, ; DE SANTIS, Fulvio; Gubbiotti, Stefania; Sambucini, Valeria. - In: JOURNAL OF BIOPHARMACEUTICAL STATISTICS. - ISSN 1054-3406. - STAMPA. - 26:(2016), pp. 966-977. [10.1080/10543406.2016.1148719]
Continuous endpoints in Bayesian two-stage designs
BRUTTI, Pierpaolo;DE SANTIS, Fulvio;GUBBIOTTI, STEFANIA;SAMBUCINI, Valeria
2016
Abstract
Single-arm two-stage designs for phase II of clinical trials typically focus on a binary endpoint obtained by dichotomising an underlying continuous measure of treatment efficacy. To avoid the resulting loss of information, we propose a two-stage design based on a Bayesian predictive approach that directly uses the original continuous endpoint. Numerical results are provided with reference to phase II cancer trials aimed at assessing tumour shrinking effect of an experimental treatment.File | Dimensione | Formato | |
---|---|---|---|
Brutti_continuous-endpoints_2016.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
641.67 kB
Formato
Adobe PDF
|
641.67 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.